Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when …
Cancer is still the leading cause of death globally. The approval of the therapeutic use of
monoclonal antibodies against immune checkpoint molecules, notably those that target the …
monoclonal antibodies against immune checkpoint molecules, notably those that target the …
TMB or not TMB as a biomarker: That is the question
Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of therapeutic
options for many cancers. These treatments have demonstrated improved efficacy and often …
options for many cancers. These treatments have demonstrated improved efficacy and often …
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
W Qian, M Zhao, R Wang, H Li - Journal of Hematology & Oncology, 2021 - Springer
Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory
pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death …
pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death …
[HTML][HTML] The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer …
A Galvano, V Gristina, U Malapelle, P Pisapia, F Pepe… - ESMO open, 2021 - Elsevier
Background The role of tumor mutational burden (TMB) is still debated for selecting
advanced non-oncogene addicted non-small-cell lung cancer (NSCLC) patients who might …
advanced non-oncogene addicted non-small-cell lung cancer (NSCLC) patients who might …
Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti-PD1/PD-L1 immunotherapy in non …
F Ghiringhelli, F Bibeau, L Greillier, JD Fumet, A Ilie… - …, 2023 - thelancet.com
Summary Background Anti-PD-1 and PD-L1 antibodies (mAbs) are approved
immunotherapy agents to treat metastatic non-small cell lung cancer (NSCLC) patients. Only …
immunotherapy agents to treat metastatic non-small cell lung cancer (NSCLC) patients. Only …
Review of the immune checkpoint inhibitors in the context of cancer treatment
NA Alturki - Journal of Clinical Medicine, 2023 - mdpi.com
Checkpoint proteins are an integral part of the immune system and are used by the tumor
cells to evade immune response, which helps them grow uncontrollably. By blocking these …
cells to evade immune response, which helps them grow uncontrollably. By blocking these …
Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data
Quantifying the effectiveness of different cancer therapies in patients with specific tumor
mutations is critical for improving patient outcomes and advancing precision medicine. Here …
mutations is critical for improving patient outcomes and advancing precision medicine. Here …
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy
EM Brozos-Vázquez, R Díaz-Peña… - Cancer Immunology …, 2021 - Springer
Immunotherapy has been one of the great advances in the recent years for the treatment of
advanced tumors, with nonsmall-cell lung cancer (NSCLC) being one of the cancers that …
advanced tumors, with nonsmall-cell lung cancer (NSCLC) being one of the cancers that …
First-line immune-checkpoint inhibitors in non-small cell lung cancer: current landscape and future progress
Z Huang, W Su, T Lu, Y Wang, Y Dong, Y Qin… - Frontiers in …, 2020 - frontiersin.org
Lung cancer is one of the most common cancers and the leading cause of cancer-related
deaths worldwide. Most of these patients with non-small cell lung cancer (NSCLC) present …
deaths worldwide. Most of these patients with non-small cell lung cancer (NSCLC) present …
VISTA: a promising target for cancer immunotherapy?
M Tagliamento, E Agostinetto, R Borea… - ImmunoTargets and …, 2021 - Taylor & Francis
Agents targeting the B7 family co-inhibitory receptors cytotoxic T-lymphocyte antigen-4
(CTLA-4) and programmed cell death protein-1 (PD-1), or its ligand (PD-L1), have a pivotal …
(CTLA-4) and programmed cell death protein-1 (PD-1), or its ligand (PD-L1), have a pivotal …